9.18
+2.46%
Close of 9 Nov 2026, in BRL
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Blau Farmaceutica
Its shares trade on B3 under the ticker BLAU3.SA. It has been listed since 19 April 2021. In the fiscal year to 31 December 2025, it reported revenue of BRL 1.70bn and net income of BRL 295.0m. At that date it held total assets of BRL 3.64bn and shareholders' equity of BRL 2.27bn.
Blau Farmacêutica SA engages in manufacturing of pharmaceuticals. The company is headquartered in Cotia, Sao Paulo. The company went IPO on 2021-04-19. The firm focuses on the development, production and commercialization of medicines, which aim at treatment in the areas of oncology, nephrology, hematology and infectology, among others. Its product lines includes biopharmaceuticals, biosimilars, oncological - injectable, oncological - oral, blood products, antiviral and antiretrovirals, uterine stimulators, anaesthetics, antithrombotics, thrombolytics, female health care, antibiotics, non-beta lactams, cephalosporin, chloramphenicol, acid pumper inhibitor and other hospital products. The firm operates in Brazil, Argentina, Colombia, Peru, Uruguay, Chile and the United States, having a pharmaceutical industrial complex composed of five industrial plants, dedicated to the production of biological, biotechnological and oncological medicines, antibiotics, injectable anesthetics and biotechnological inputs.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 19 Apr 2021
- Employees
- 1,700
- Website
- blau.com ↗
Leadership
Pay as last reported
- Marcelo HahnChief Executive Officer
- Ms. Simone AgraMember of the Board
- Antonio BuzaidMember of the Board
- Rodolfo Alfredo Gerardo HahnMember of the Board
- Jose Antonio Miguel NetoMember of the Board
- Andrea SantosMember of the Board
- Roberto AltieriDirector
- Roberto MoraisDirector
- Douglas RodriguesDirector
- Eliza SaitoDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company has 1,700 employees
- Operates in multiple countries including Brazil, Argentina, Colombia, Peru, Uruguay, Chile, and the United States
- Owns five industrial plants for pharmaceutical production
Weaknesses
- No specific weaknesses mentioned in the provided information
- No financial data or performance metrics provided
- No details on market share or competitive positioning
Opportunities
- Expansion into new markets within the listed countries
- Growth in biopharmaceuticals and biosimilars sectors
- Potential for increased production of oncological and hematology medicines
Threats
- No specific threats mentioned in the provided information
- No mention of regulatory challenges or competition
- No data on potential market saturation or economic downturns
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.